(Lung Cancer) anti-PD-L1 antibody Approved in Japan as First Immune Checkpoint Inhibitor for Adjuvant Therapy
(Lung Cancer) anti-PD-L1 antibody Approved in Japan as First Immune Checkpoint Inhibitor for Adjuvant Therapy
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
(Lung Cancer) anti-PD-L1 antibody Approved in Japan as First Immune Checkpoint Inhibitor for Adjuvant Therapy
- June 8, 2022
- 1 min read
On May 26, 2022, Chugai Pharmaceutical Co., Ltd. announced that anti-PD-L1 antibody (intravenous infusion 1200 mg) received approval as Japan's first cancer immunotherapy drug indicated for use as adjuvant therapy in PD-L1-positive non-small cell lung cancer.
Lung cancer is a major cause of cancer death in Japan. Non-small cell lung cancer is broadly classified histologically into small cell lung cancer and non-small cell lung cancer, with non-small cell lung cancer accounting for approximately 85% of all lung cancer patients.
This approval was based on the results of the IMpower010 Phase 3 clinical trial, which evaluated the efficacy and safety of anti-PD-L1 antibody as adjuvant therapy in patients with Stage II and IIIA non-small cell lung cancer with PD-L1 expression of 1% or higher. The results showed that patients treated with anti-PD-L1 antibody experienced prolonged progression-free survival.
In a press release, Osamu Okuda, President and CEO of Chugai Pharmaceutical Co., Ltd., stated: "This approval of anti-PD-L1 antibody is extremely important for early-stage cancer, as it offers the possibility of preventing recurrence and achieving a cure — the ultimate goal of treatment. Over the past decade, there has been little significant progress in the treatment of early-stage lung cancer. anti-PD-L1 antibody is the first immunotherapy drug to demonstrate a reduction in the risk of recurrence and death, and we will continue to contribute to adjuvant therapy for non-small cell lung cancer."
Source: https://www.chugai-pharm.co.jp/news/detail/20220526170000_1219.html
-
Investigational Drug
-
Immunotherapy
(Lung Cancer) Topotecan and Topotecan + Berzosertib in Phase 2 Clinical Trial Results. (Lung Cancer) Is anti-HER2 antibody-drug conjugate Effective for HER2-Mutated Non-Small Cell Lung Cancer? (Lung Cancer) Is the Anti-B7-H3 Antibody-Drug Conjugate DS-7300 Effective?
Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free (initial direction only; further services are quoted separately); an advisor will help you clarify the next steps.